However, in the Canadian cancer trials group CO.26 study, elevated plasma TMB levels (≥28 muts/Mb) showed a predictable response to anti-PD-L1 agent durvalumab and anti-CTLA4 agent tremelimumab combination therapy in MSS colon cancer patients (57). This evidence concerns the gene CD274 and cancer.